Interim report
Page 1
Consolidated Financial Results for the Three Months Ended June 30 , 2026 Terumo Corporation ( IFRS ) Company name : Listing : Securities code : URL : Representative : Inquiries : Telephone : TERUMO CORPORATION Tokyo Stock Exchange 4543 https://www.terumo.com/ Hikaru Samejima , Chief Executive Officer Jin Hagimoto , Chief Financial Officer , Chief Information Officer + 81-3-6742-8550 Scheduled date to commence dividend payments : - Preparation of supplementary material on financial results : Yes Holding of financial results briefing : Accouting Standards Fou FASF MEMBERSHIP August 7 , 2026 Yes ( for Securities analysts , Institutional investors ) ( Yen amounts are rounded down to millions , unless otherwise noted . ) 1. Consolidated financial results for the three months ended June 30 , 2026 ( from April 1 , 2026 to June 30 , 2026 ) ( 1 ) Consolidated operating results ( cumulative ) ( Percentages indicate year on year changes . ) Revenue Operating profit Profit before tax Profit for the period Three months ended Millions of % yen Millions of yen Millions of % % June 30 , 2026 June 30 , 2025 311,810 259,965 19.9 0.7 89,480 55.885 60.1 25.2 yen 90,321 63.5 55.259 21.1 Millions of yen 70,426 68.3 % Profit attributable to owners of the parent Millions of yen 70,426 68.3 41,843 23.5 41,843 23.5 Total comprehensive income Millions of % % yen 99,579 406.6 19,654 ( 81.7 ) Basic earnings per share Diluted earnings per share Three months Yen Yen ended June 30 , 2026 47.74 47.73 June 30 , 2025 28.37 28.36 ( Note ) Adjusted operating profit June 2026 : 79,607 million yen June 2025 : 59,103 million yen ( 2 ) Consolidated financial position As of June 30 , 2026 March 31 , 2026 Total assets Millions of yen 2,374,093 2,312,234 Total equity Millions of yen 1,662,023 1,584,509 Equity attributable to owners of the parent Millions of yen 1,662,023 1,584,509 Ratio of equity attributable to owners of the parent to total assets % 70.0 68.5
Page 2
2. Cash dividends Annual dividends per share First quarter-end Second quarte r-end Third quarte r-end Fiscal year-end Total Yen Yen Yen Yen Yen Fiscal year ended March 31, 2026 － 15.00 － 15.00 30.00 Fiscal year ending March 31, 2027 － Fiscal year ending March 31, 2027 (Guidance) 18.00 － 18.00 36.00 (Note) Revision from the dividend guidance published most recently: None 3. Consolidated Financial Guidance for the Fiscal Year Ending March 31, 2027 (from April 1, 2026 to March 31, 2027) (Percentages indicate year on year changes.) Revenue Adjusted operating profit Operating profit Profit for the year attributable to owners of the parent Basic Earnings per share Millions of yen % Millions of yen % Millions of yen % Millions of yen % Yen Full fiscal year 1,239,000 9.5 274,500 25.1 257,500 46.0 193,100 42.1 130.91 (Note 1) Revision of guidance published most recently: Yes Please refer to the “Notice Concerning Revisions to Full-Year Consolidated Financial Guidance for Fiscal Year Ending March 31, 2027 (FY2026)” released on August 7, 2026. (Note 2) Assumed exchange rate: 1USD=155 JPY , 1EUR=180 JPY
Page 3
*Notes (1) Significant changes in the scope of consolidation during the period: None Newly included: － (Company Name: － ) Excluded : － (Company Name: － ) (2) Changes in accounting policies and changes in accounting estimates (i) Changes in accounting policies required by IFRS: Yes (ii) Changes in accounting policies other than (i): None (iii) Changes in accounting estimates: None Note: Please refer to [attached materials], page 14, “2. Condensed Quarterly Consolidated Financial Statements (5) Notes to Condensed Quarterly Consolidated Financial Statements (ii) Changes in accounting policy”. (3) Number of shares outstanding (common stock) (i) Number of shares outstanding at the end of the period (including treasury shares) As of June 30, 2026 1,480,559,680 shares As of March 31, 2026 1,480,559,680 shares (ii) Number of treasury shares at the end of the period As of June 30, 2026 5,458,187 shares As of March 31, 2026 5,476,639 shares (iii) Average number of shares during the period (cumulative from the beginning of the fiscal year) Three months ended June 30, 2026 1,475,101,010 shares Three months ended June 30, 2025 1,474,952,053 shares * Review of Japanese-language originals of the attached consolidated financial statements by certified public accountants or an audit firm: None * Explanation on appropriate use of financial guidance and other special notes 1. Forward-looking statements, including financial guidance, contained in these disclosure materials, are based on information currently available to the Company and on certain assumptions deemed reasonable by management. These statements are not intended as a promise or commitment by the Company to achieve such results. Actual results may differ materially from these statements due to a variety of factors. For the assumptions underlying the financial guidance and notes on the use of such guidance, please refer to [attached materials], page 6, “1. Overview of Financial Results (4) Future Outlook concerning Consolidated Financial Guidance”. 2. Adjusted operating profit is defined as operating profit adjusted to exclude amortization of intangible assets acquired through business combinations and non-recurring profit or loss. Adjusted operating profit is consistent with segment profit and is disclosed as it is used as a performance indicator for the Group.
Page 4
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 1 － Table of contents of attached materials 1. Overview of Financial Results ................................................................................................................................ 2 (1) Overview of Consolidated Business Results ...................................................................................................... 2 (2) Overview of Consolidated Statement of Financial Position ............................................................................... 5 (3) Cash flow trends ................................................................................................................................................. 5 (4) Future Outlook concerning Consolidated Financial Guidance ........................................................................... 6 2. Condensed Quarterly Consolidated Financial Statements ...................................................................................... 7 (1) Condensed Quarterly Consolidated Statement of Financial Position ................................................................. 7 (2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income .............................................................................................................. 9 (3) Condensed Quarterly Consolidated Statement of Changes in Equity .............................................................. 11 (4) Condensed Quarterly Consolidated Statement of Cash Flows ................................................................. ...... 12 (5) Notes to Condensed Quarterly Consolidated Financial Statements ................................................................. 14 (i) Going concern assumption ............................................................................................................................. 14 (ii) Change in accounting policy ......................................................................................................................... 14 (iii) Segment information ................................................................................................................................... 14 (iv) Material subsequent events .......................................................................................................................... 17
Page 5
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 2 － 1. Overview of Financial Results (1) Overview of Consolidated Business Results In the three months of the current fiscal year (from April 1 to June 30, 2026), the Group’s sales trended strongly amid growing demand globally and the effects of foreign exchange rates. Financial results for the three months are as follows: (Unit: Millions of yen) For the three months ended June 30, 2025 For the three months ended June 30, 2026 Growth (%) Growth excluding FX impact (%) Revenue 259,965 311,810 19.9 9.4 Gross profit 145,467 178,538 22.7 13.3 Adjusted operating profit 59,103 79,607 34.7 25.3 Operating profit 55,885 89,480 60.1 48.7 Profit before tax 55,259 90,321 63.5 - Profit for the period 41,843 70,426 68.3 - Profit for the period attributable to owners of the parent 41,843 70,426 68.3 - Revenue by geographic area for the three months is as follows: (Unit: Millions of yen) Geographic area For the three months ended June 30, 2025 For the three months ended June 30, 2026 Growth (%) Growth excluding FX impact (%) Americas 100,503 126,140 25.5 12.2 Europe 54,299 67,389 24.1 11.9 China 22,935 27,955 21.9 3.4 Asia and others 29,419 35,558 20.9 10.0 Overseas total 207,158 257,044 24.1 10.8 Japan 52,807 54,765 3.7 3.7 Total 259,965 311,810 19.9 9.4
Page 6
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 3 － Revenue Revenue totaled ¥311.8 billion, an increase of 19.9% compared to the same period of the previous fiscal year. Overseas, revenue increased by 24.1% year on year, due to expansion in the Terumo Interventional Systems division, centered on access devices, and growth in the key businesses of the Blood and Cell Technologies Company, along with the effects of foreign exchange rates. In Japan, revenue increased by 3.7% year on year, due to strong sales in the Terumo Neuro division, the Hospital Care Solutions division, and the Pharmaceutical Solutions division. Profit Gross profit totaled ¥178.5 billion, an increase of 22.7% compared to the same period of the previous fiscal year, primarily due to higher revenue and the refund of U.S. tariffs. Adjusted operating profit totaled ¥79.6 billion, an increase of 34.7% compared to the same period of the previous fiscal year, because of the higher gross profit. Operating profit, profit for the period and profit for the period attributable to owners of the parent all increased due to the increase in gross profit and the recognition of settlement proceeds. The Group discloses adjusted operating profit as a supplementary performance indicator that is not defined under IFRS, the accounting standards applied by the Group. Adjusted operating profit is defined as operating profit adjusted to exclude amortization of intangible assets acquired through business combinations and non-recurring profit or loss, and is consistent with segment profit. The Group uses adjusted operating profit for management purposes to assess the performance of each business as it aims to achieve sustainable growth over the mid- to long-term. The Group also believes that this indicator provides useful information for users of the financial statements in evaluating the Group’s performance.
Page 7
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 4 － Revenue results of the reportable segments are as follows: (Unit: Millions of yen) Segment For the three months ended June 30, 2025 For the three months ended June 30, 2026 Growth (%) Growth excluding FX impact (%) Cardiac and Vascular Company Revenue 157,827 188,141 19.2 7.3 (Overseas) 143,773 174,215 21.2 8.1 (Japan) 14,054 13,925 (0.9) (0.9) Medical Care Solutions Company Revenue 50,402 56,587 12.3 8.5 (Overseas) 14,393 18,705 30.0 16.1 (Japan) 36,009 37,881 5.2 5.2 Blood and Cell Technologies Company Revenue 51,646 60,776 17.7 6.1 (Overseas) 48,991 57,897 18.2 6.0 (Japan) 2,654 2,879 8.5 8.5 Terumo Organ Technologies Revenue - 6,225 - - (Overseas) - 6,225 - - (Japan) - - - - Cardiac and Vascular Company Overseas, revenue increased by 21.2% year on year, due to growth across all businesses, particularly in the Terumo Interventional Systems division. In Japan, despite strong sales in the Terumo Neuro division, revenue decreased by 0.9% year on year due to lower sales in the Terumo Aortic division. As a result, global revenue increased by 19.2% compared to the same period of the previous fiscal year to ¥188.1 billion. Medical Care Solutions Company In Japan, revenue increased by 5.2% year on year, driven by growth in the Hospital Care Solutions and the Pharmaceutical Solutions divisions. Overseas, revenue increased by 30.0% year on year, driven by sales growth primarily in Europe. As a result, global revenue increased by 12.3% compared to the same period of the previous fiscal year to ¥56.6 billion. Blood and Cell Technologies Company Overseas, revenue increased by 18.2% year on year as the key businesses in Europe and North America continued to grow. In Japan, revenue increased by 8.5% year on year, supported by solid sales of blood collection-related products. As a result, global revenue increased by 17.7% compared to the same period of the previous fiscal year to ¥60.8 billion. Terumo Organ Technologies Following the acquisition of all shares of OrganOx Limited and its consolidation as a wholly owned subsidiary on October 29, 2025, the financial results of OrganOx Limited have been included in the Group’s consolidated results from the acquisition date onward. Revenue in this segment totaled ¥6.2 billion, driven by business expansion primarily in the North American market.
Page 8
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 5 － (2) Overview of Consolidated Statement of Financial Position Total assets increased by ¥61.9 billion to ¥2,374.1 billion. This was mainly attributable to an increase of ¥34.1 billion in cash and cash equivalents due to business expansion, an increase of ¥9.0 billion in other financial assets due to the rise in market prices of listed stocks, and an increase of ¥9.0 billion in trade and other receivables due to the recognition of government grants. Total liabilities decreased by ¥15.7 billion to ¥712.1 billion. This was mainly attributable to a decrease of ¥13.5 billion in other current liabilities due to bonus payments. Total equity increased by ¥77.5 billion to ¥1,662.0 billion. This was mainly attributable to an increase of ¥70.4 billion resulting from profit for the period and an increase of ¥29.2 billion in other comprehensive income associated with the yen depreciation, which offset a decrease of ¥22.1 billion due to the payments for dividends from retained earnings. (3) Cash flow trends (Millions of yen) For the three months ended June 30, 2025 For the three months ended June 30, 2026 Change Cash flows from operating activities 32,639 74,478 41,838 Cash flows from investing activities (21,912) (28,273) (6,361) Cash flows from financing activities (25,830) (16,191) 9,638 Cash and cash equivalents at the end of the period 204,294 314,633 110,338 Cash flows from operating activities Net cash provided by operating activities amounted to ¥74.5 billion. The main factors were profit before tax of ¥90.3 billion, depreciation and amortization of ¥27.2 billion, and income taxes paid of ¥24.0 billion. Cash flows from investing activities Net cash used in investing activities amounted to ¥28.3 billion. The main factors were ¥12.6 billion for purchase of property, plant and equipment following capital expenditures for manufacturing facilities, ¥6.3 billion for payments for acquisition of shares of subsidiaries, affiliates and other businesses due to additional payments resulting from the finalization of the acquisition consideration of OrganOx Limited, and ¥6.2 billion for purchase of intangible assets following investment in new IT systems. Cash flows from financing activities Net cash used in financing activities amounted to ¥16.2 billion. The main factors were repayments of long-term borrowings of ¥160.0 billion, payments for dividends of ¥21.9 billion, redemption of corporate bonds of ¥10.0 billion, proceeds from long-term borrowings of ¥98.8 billion, and proceeds from issue of corporate bonds of ¥79.3 billion. In addition to the above, there was a ¥4.1 billion increase from the effect of exchange rate changes on cash and cash equivalents. As a result, the balance of cash and cash equivalents as of the end of the period stood at ¥314.6 billion, up ¥34.1 billion from the end of the previous fiscal year.
Page 9
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 6 － (4) Future Outlook concerning Consolidated Financial Guidance We revised upward our full-year consolidated financial guidance for adjusted operating profit, operating profit, and profit for the year attributable to owners of the parent, reflecting the refund of U.S. tariffs and the recognition of settlement proceeds. For details, please refer to the “Notice Concerning Revisions to Full-Year Consolidated Financial Guidance for Fiscal Year Ending March 31, 2027 (FY2026)” released on August 7, 2026.
Page 10
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 7 － 2. Condensed Quarterly Consolidated Financial Statements (1) Condensed Quarterly Consolidated Statement of Financial Position （Unit: Millions of yen） As of March 31, 2026 As of June 30, 2026 Assets Current assets Cash and cash equivalents 280,494 314,633 Trade and other receivables 214,927 223,901 Other current financial assets 236 159 Inventories 335,634 341,109 Current tax assets 2,644 1,666 Other current assets 27,102 25,135 Total current assets 861,040 906,605 Non-current assets Property, plant and equipment 506,481 508,691 Goodwill and intangible assets 803,410 809,145 Investments accounted for using the equity method 1,544 2,727 Other non-current financial assets 65,085 74,175 Deferred tax assets 45,107 43,387 Other non-current assets 29,565 29,360 Total non-current assets 1,451,194 1,467,488 Total assets 2,312,234 2,374,093
Page 11
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 8 － （Unit: Millions of yen） As of March 31, 2026 As of June 30, 2026 Liabilities and Equity Liabilities Current liabilities Trade and other payables 89,756 79,793 Bonds and borrowings 279,886 179,942 Other current financial liabilities 8,969 9,295 Current tax liabilities 36,830 32,438 Provisions 260 274 Other current liabilities 125,028 111,532 Total current liabilities 540,731 413,275 Non-current liabilities Bonds and borrowings 99,910 209,520 Other non-current financial liabilities 39,257 39,298 Deferred tax liabilities 25,671 25,755 Retirement benefit liabilities 6,214 6,155 Provisions 921 928 Other non-current liabilities 15,018 17,136 Total non-current liabilities 186,993 298,794 Total liabilities 727,725 712,070 Equity Share capital 38,716 38,716 Capital surplus 51,720 51,782 Treasury shares (14,517) (14,468) Retained earnings 1,116,479 1,164,807 Other components of equity 392,110 421,185 Total equity attributable to owners of the parent 1,584,509 1,662,023 Total equity 1,584,509 1,662,023 Total liabilities and equity 2,312,234 2,374,093
Page 12
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 9 － (2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income (Condensed Quarterly Consolidated Statement of Profit or Loss) （Unit: Millions of yen） For the three months ended June 30, 2025 For the three months ended June 30, 2026 Revenue 259,965 311,810 Cost of sales 114,498 133,271 Gross profit 145,467 178,538 Selling, general and administrative expenses 91,981 109,699 Other income 4,133 21,198 Other expenses 1,733 556 Operating profit 55,885 89,480 Finance income 873 2,381 Finance costs 1,278 1,476 Share of profit/(loss) of investments accounted for using the equity method (221) (63) Profit before tax 55,259 90,321 Income tax expenses 13,415 19,894 Profit for the period 41,843 70,426 Attributable to: Owners of the parent 41,843 70,426 Total profit for the period 41,843 70,426 Earnings per share Basic earnings per share (yen) 28.37 47.74 Diluted earnings per share (yen) 28.36 47.73
Page 13
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 10 － (Condensed Quarterly Consolidated Statement of Comprehensive Income) （Unit: Millions of yen） For the three months ended June 30, 2025 For the three months ended June 30, 2026 Profit for the period 41,843 70,426 Other comprehensive income Items that will not be reclassified to profit or loss Changes in financial assets measured at fair value through other comprehensive income (890) 2,095 Total items that will not be reclassified to profit or loss (890) 2,095 Items that are or may be reclassified subsequently to profit or loss Exchange differences on translation of foreign operations (21,298) 27,445 Cost of hedging - (388) Total items that are or may be reclassified subsequently to profit or loss (21,298) 27,057 Total other comprehensive income for the period (22,188) 29,152 Total comprehensive income for the period 19,654 99,579 Attributable to: Owners of the parent 19,654 99,579 Total comprehensive income for the period 19,654 99,579 (Note) Items in the above statement are net of tax.
Page 14
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 11 － (3) Condensed Quarterly Consolidated Statement of Changes in Equity For the three months ended June 30, 2025 （Unit: Millions of yen） Equity attributable to owners of the parent Share capital Capital surplus Treasury shares Retained earnings Other components of equity Total Total equity Balance as of April 1, 2025 38,716 51,725 (14,866) 1,016,160 276,800 1,368,535 1,368,535 Profit for the period - - - 41,843 - 41,843 41,843 Other comprehensive income - - - - (22,188) (22,188) (22,188) Total comprehensive income - - - 41,843 (22,188) 19,654 19,654 Acquisition of treasury shares - - (0) - - (0) (0) Disposal of treasury shares - (2) 2 - (0) 0 0 Dividends - - - (19,174) - (19,174) (19,174) Transfer from retained earnings to capital surplus -2 -( 2 ) - - - Share-based payments - 57 (0) - - 56 56 Total transactions with owners of the parent - 57 1 (19,176) (0) (19,118) (19,118) Balance as of June 30, 2025 38,716 51,782 (14,865) 1,038,827 254,610 1,369,071 1,369,071 For the three months ended June 30, 2026 （Unit: Millions of yen） Equity attributable to owners of the parent Share capital Capital surplus Treasury shares Retained earnings Other components of equity Total Total equity Balance as of April 1, 2026 38,716 51,720 (14,517) 1,116,479 392,110 1,584,509 1,584,509 Profit for the period - - - 70,426 - 70,426 70,426 Other comprehensive income - - - - 29,152 29,152 29,152 Total comprehensive income - - - 70,426 29,152 99,579 99,579 Acquisition of treasury shares - - (0) - - (0) (0) Disposal of treasury shares - (23) 49 - (26) 0 0 Dividends - - - (22,126) - (22,126) (22,126) Transfer from retained earnings to capital surplus - 23 - (23) - - - Transfer from other components of equity to retained earnin gs -- -5 0 ( 5 0 ) - - Share-based payments - 61 (0) - - 61 61 Total transactions with owners of the parent - 61 48 (22,098) (76) (22,064) (22,064) Balance as of June 30, 2026 38,716 51,782 (14,468) 1,164,807 421,185 1,662,023 1,662,023
Page 15
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 12 － (4) Condensed Quarterly Consolidated Statement of Cash Flows (Unit: Millions of yen) For the three months ended June 30, 2025 For the three months ended June 30, 2026 Cash flows from operating activities Profit before tax 55,259 90,321 Depreciation and amortization 21,183 27,190 Impairment losses 13 - Share of (profit)/loss of investments accounted for using the equity method 221 63 Increase/(decrease) in retirement benefit assets or liabilities 509 180 Interest and dividend income (851) (1,656) Interest expenses 475 1,476 Foreign exchange (gain)/loss (2,118) (1,873) (Gain)/loss on sale and disposal of property, plant and equipment 65 12 (Increase)/decrease in trade and other receivables (5,942) (6,589) (Increase)/decrease in inventories (10,501) (3,176) Increase/(decrease) in trade and other payables (2,453) (3,726) Others (8,113) (4,322) Sub-total 47,749 97,900 Interest and dividend income received 834 1,841 Interest expenses paid (723) (1,226) Income taxes paid (15,220) (24,037) Net cash provided by operating activities 32,639 74,478 Cash flows from investing activities Payments into time deposits (126) (558) Proceeds from withdrawal of time deposits 200 335 Payments for purchase of property, plant and equipment (16,994) (12,608) Proceeds from sale of property, plant and equipment 46 48 Payments for purchase of intangible assets (3,287) (6,211) Proceeds from government grants 67 224 Payments for purchase of financial instruments (1,750) (3,317) Proceeds from sale of financial instruments - 100 Payments for acquisition of shares of subsidiaries, affiliates and other businesses (67) (6,285) Net cash used in investing activities (21,912) (28,273)
Page 16
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 13 － (Unit: Millions of yen) For the three months ended June 30, 2025 For the three months ended June 30, 2026 Cash flows from financing activities Increase/(decrease) in short-term borrowings and commercial paper 10,000 - Proceeds from long-term borrowings - 98,770 Repayments of long-term borrowings (15,000) (160,000) Proceeds from issue of corporate bonds - 79,262 Redemption of corporate bonds - (10,000) Repayments of lease liabilities (1,845) (2,326) Payments for purchase of treasury shares (0) (0) Payments for dividends (18,984) (21,898) Net cash used in financing activities (25,830) (16,191) Effect of exchange rate changes on cash and cash equivalents (2,475) 4,126 Net increase/(decrease) in cash and cash equivalents (17,578) 34,139 Cash and cash equivalents at the beginning of the period 221,872 280,494 Cash and cash equivalents at the end of the period 204,294 314,633
Page 17
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 14 － (5) Notes to Condensed Quarterly Consolidated Financial Statements (i) Going concern assumption Not applicable (ii) Change in accounting policy The Group has adopted the standard and interpretation below from the first quarter of the fiscal year ending March 31, 2027. Standard/Interpretation Outline of the new standards, interpretations and amendments IFRS 9 IFRS 7 Financial Instruments Financial Instruments: Disclosures Amendments to the classification, measurement and disclosure of financial instruments (IFRS 9 and IFRS 7) ・Clarifying the classification of financial assets with environmental, social and governance (ESG) and similar features ・Derecognition of a financial liability settled through electronic transfer ・Disclosure regarding investments in equity instruments designated at fair value through other comprehensive income There is no material effect of adopting the amendment on the Group’s condensed quarterly consolidated financial statements. (iii) Segment information (1) General information on reportable segments The Group’s reportable segments are components of the Group for which discrete financial information is available and which are regularly reviewed by the Board of Directors for the purposes of allocating management resources and evaluating business performance. The Group has adopted an internal company structure organized by product groups. Each internal company headquarters formulates comprehensive strategies for its respective products in both Japan and overseas and conducts its business activities accordingly. Following the acquisition of all shares of OrganOx Limited on October 29, 2025, making it a wholly owned subsidiary, “Terumo Organ Technologies” was added as a reportable segment in the previous fiscal year. Accordingly, the Group has designated four reportable segments based on its internal company structure and product group classifications: the Cardiac and Vascular Company, the Medical Care Solutions Company, the Blood and Cell Technologies Company, and Terumo Organ Technologies.
Page 18
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 15 － (2) Reportable segment information Revenue and performance by the reporting segments of the Group are as follows. For the three months ended June 30, 2025 (Unit: Millions of yen) Reportable Segments Adjustments (Note 1) Amount recorded on condensed quarterly consolidated financial statements Cardiac and Vascular Company Medical Care Solutions Company Blood and Cell Technologies Company Terumo Organ Technologies Total Revenue Revenue from sales to external customers 157,827 50,402 51,646 - 259,876 89 259,965 Segment profit (Adjusted o p e r a t i n g profit) 45,678 6,664 7,036 - 59,378 (274) 59,103 (Adjustment items) Amortization of intangible assets acquired through business combinations (2,366) - (2,782) - (5,148) 74 (5,073) Non-recurring profit or loss (Note 2) 1,855 Operating profit 55,885 Finance income 873 Finance costs (1,278) Share of profit/(loss) of investment accounted for using the equity method (221) Profit before tax 55,259 (Note 1) Amounts in Adjustments are as follows: (1) ¥89 million adjustment to Revenue from sales to external customers is mainly proceeds from outward temporary staffing that is not attributable to reportable segments. (2) ¥(274) million adjustment to Segment profit consists of ¥(450) million for preparation expenses to comply with Medical Device Regulation in the EU and ¥205 million for inventories. (Note 2) ¥1,855 million Non-recurring profit or loss mainly includes ¥3,152 million for loss compensation due to the termination of the new contract manufacturing project with a pharmaceutical company and ¥(1,277) million for business reorganization expenses.
Page 19
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 16 － For the three months ended June 30, 2026 (Unit: Millions of yen) Reportable Segments Adjustments (Note 1) Amount recorded on condensed quarterly consolidated financial statements Cardiac and Vascular Company Medical Care Solutions Company Blood and Cell Technologies Company Terumo Organ Technologies Total Revenue Revenue from sales to external customers 188,141 56,587 60,776 6,225 311,730 79 311,810 Segment profit (Adjusted o p e r a t i n g profit) 59,971 7,076 11,135 940 79,123 484 79,607 (Adjustment items) Amortization of intangible assets acquired through business combinations (2,592) (8) (2,936) (1,593) (7,130) (81) (7,211) Non-recurring profit or loss (Note 2) 17,084 Operating profit 89,480 Finance income 2,381 Finance costs (1,476) Share of profit/(loss) of investment accounted for using the equity method (63) Profit before tax 90,321 (Note 1) Amounts in Adjustments are as follows: (1) ¥79 million adjustment to Revenue from sales to external customers is mainly proceeds from outward temporary staffing that is not attributable to reportable segments. (2) ¥484 million adjustment to Segment profit consists of ¥(333) million for preparation expenses to comply with Medical Device Regulation in the EU and ¥586 million for inventory adjustments. (Note 2) ¥17,084 million Non-recurring profit or loss includes ¥20,110 million for recognition of settlement proceeds and ¥(2,561) million for expense related to the inventory step-up arising from fair value measurement of acquired assets in the acquisition of OrganOx Limited.
Page 20
Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2026 － 17 － (iv) Material subsequent events Issuance of bonds In accordance with the resolution of the Board of Directors held on March 19, 2026, the Company issued unsecured straight bonds with a payment date of July 24, 2026, under the following terms and conditions. Terumo Corporation 12th series Unsecured Straight Bonds with inter-bond pari passu clause (2-year bond) 1. Issue size: ¥40 billion 2. Issue price: 100 yen per 100 yen of each bond amount 3. Coupon rate: 1.716% per annum 4. Payment due date: July 24, 2026 5. Maturity date: July 24, 2028 6. Redemption method: full redemption upon maturity 7. Use of proceeds: to be allocated to a repayment of borrowings due at the end of October 2026